Amneal Pharmaceuticals (AMRX) Proxy filing summary

Executive summary

• Announced a definitive agreement to acquire Kashiv BioSciences, creating a global biosimilar leader with direct access to over $300B in global biologic loss of exclusivity (LOE) opportunities over the next decade, including $234B in the U.S.

• The acquisition is highly strategic and complementary, integrating Kashiv's R&D and manufacturing with commercial scale, and builds on a decade-long partnership.

• The combined entity will have a robust biosimilar pipeline, targeting multiple launches annually and expanding international reach, with 12+ commercial and 20+ pipeline biosimilars expected by 2030.

• Transaction expected to close in the second half of 2026, subject to shareholder and regulatory approvals.

Voting matters and shareholder proposals

• Shareholder approval is required for the acquisition of Kashiv BioSciences.

• The transaction has been approved by the Board of Directors and a Committee of Independent Directors, given the related party nature of the deal.

Board of directors and corporate governance

• The Committee of Independent Directors engaged external management, investment banking, regulatory, and legal consultants for due diligence and negotiation.

• Information about directors and executive officers is available in the 2026 annual meeting proxy statement.